Our second, an alpha-emitting actinium-based compound, CLR121-225, or referred to as CLR225. Our OJ emitting radioconjugate product candidate, CLR125, potentially represents the highest level of precision in targeted radiotherapy, with its emissions traveling only a few nanometers.

Aug 14, 2025 / receipt, needs a key / Jared Lancourt, COO | earnings call 2025-08-14 | transcript 78980747-702c-4e7e-924c-3a510d2ac193 | chars 10734-11016 | segment 10

Estimated Total Study Cost $42M: ~ $15M to accelerated approval and $30M to full approval (PFS data)

ir_statement / Sep 13, 2026 / receipt

Phase 3 Confirmatory Study Required for U.S and EU Full Approval

ir_statement / Sep 13, 2026 / receipt

EMA Conditional Marketing Authorization submission based upon U.S. confirmatory study timing

ir_statement / Sep 13, 2026 / receipt

Evaluate US and EU iopofosine I 131 development and commercialization partnerships

ir_statement / Sep 13, 2026 / receipt

Enrollment: 200 patients (100/arm)

ir_statement / Sep 13, 2026 / receipt

Estimated Total Study Cost $42M: ~ $15M to accelerated approval and $30M to full approval (PFS data)

ir_statement / Sep 13, 2026 / receipt

Phase 3 Confirmatory Study Required for U.S and EU Full Approval

ir_statement / Sep 13, 2026 / receipt

Select US and EU iopofosine I 131 development and commercialization partnerships / approaches

ir_statement / Sep 13, 2026 / receipt

Strategic Growth and Expansion

ir_statement / Sep 13, 2026 / receipt